Addax Biosciences has developed Gaf, a safer and more effective alternative to formaldehyde for biological sample preservation, supported by an investment from Fintech Partners to enhance health safety in laboratories.

Target Information

Addax Biosciences, a spinoff from the University of Turin, has developed an innovative biotechnological solution known as Glyoxal Acid Free (Gaf), which has the potential to replace formaldehyde in laboratory settings. This groundbreaking formulation enhances the stability and integrity of DNA, making it a safer alternative for medical professionals who handle hazardous materials regularly. The Gaf solution addresses the concerns associated with formaldehyde, which has been classified as a carcinogen by the EU for several years.

The development of Gaf stems from over a decade of research led by Giovanni Bussolati, an esteemed professor at the University of Turin, along with his daughter, Benedetta Bussolati, who specializes in Laboratory Medicine. Gaf not only promises to maintain biological sample integrity more effectively than formalin but also offers significant cost savings in management and disposal, potentially yielding annual savings of €40,000 to €120,000 for hospitals, as highlighted by a Deloitte study.

Industry Overview

The biotechnological landscape in Italy is ripe for innovation, particularly in the medical and laboratory sectors. Italy has a well-established reputation for research and development, particularly in life sciences, and conti